The system was developed by Senseonics and brought to people with diabetes by Ascensia Diabetes Care. (Credit: Myriams-Fotos from Pixabay)
Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, and Ascensia Diabetes Care, its commercialization partner, have announced the first commercial patient has been implanted with Eversense® E3, kicking off the launch of the next-generation CGM System in the U.S. The Eversense E3 Sensor was approved by the FDA in February and is the longest lasting CGM available in the U.S.
“The accuracy, duration and implantable form of Eversense E3 combine to provide diabetes patients confidence and convenience never available previously,” said Bantwal S. Baliga, MD: MRCP (U.K.), Director of East Alabama Endocrinology, and the first physician to insert the extended life sensor now that it is commercially available. “This next-generation implantable system has been designed with patients in mind by offering 6-months of sensor life. It also offers unique benefits like discrete on-body vibratory alerts through a removable transmitter that provides patients wear time flexibility without ever having to waste a sensor. It is an important offering for patients wanting accuracy, protection, and convenience.”
The Eversense E3 CGM System, developed by Senseonics and brought to people with diabetes by Ascensia Diabetes Care, offers:
- The longest lasting CGM available, with a 6-month sensor wear duration, with essentially two sensor insertion and removal procedures per year
- Exceptional accuracy, with a mean absolute relative difference (MARD) of 8.5% demonstrated in the PROMISE Study for the duration of sensor wear
- A fully implantable fluorescence-based sensor, with a removable smart transmitter that provides discreet on-body vibratory alerts and transmits data to a mobile app
- Reduced calibrations compared to the previous generation Eversense CGM Systems
“We are pleased with the patient and health care provider excitement surrounding the Eversense E3 launch,” said Tim Goodnow, President and Chief Executive Officer. “Today marks a major milestone in the history of diabetes care, advancing our Eversense CGM offering so that patients with diabetes can live more freely. We are excited the Eversense E3 is now available to millions of diabetes patients across the U.S.”
Source: Company Press Release